Gracell Biotechnologies Granted FDA Orphan Drug Designation

Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma

Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma

prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , United States , Shanghai , Suzhou , Jiangsu , Martina Sersch , Marvin Tang , Gracell Fas , Exchange Commission , Prnewswire Gracell Biotechnologies Inc , Gracell Biotechnologies Inc , International Myeloma Working Group , Drug Administration , Nasdaq , Orphan Drug Designation , Chief Medical Officer , Refractory Multiple Myeloma , Multiple Myeloma , Drug Designation , Mayo Stratification , Risk Adapted Therapy , Private Securities Litigation Reform Act ,